{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:24:21Z","timestamp":1789925061013,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuropharm.2025.110812","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:38:47Z","timestamp":1766475527000},"page":"110812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting treatment-resistant social anxiety with sitagliptin: Effects on social fear and comorbid depressive-like behavior in a preclinical model"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-3181","authenticated-orcid":false,"given":"Iulia","family":"Zoicas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neuropharm.2025.110812_bib1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11011-015-9656-2","article-title":"Sitagliptin protects proliferation of neural progenitor cells in diabetic mice","volume":"30","author":"Bachor","year":"2015","journal-title":"Metab. Brain Dis."},{"issue":"23","key":"10.1016\/j.neuropharm.2025.110812_bib2","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15515","article-title":"Saxagliptin: a potential doping agent? A randomized, double-blinded, placebo-controlled, and crossover pilot study in young active men","volume":"10","author":"Bourdillon","year":"2022","journal-title":"Physiol Rep"},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110812_bib3","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.3390\/ijms25168685","article-title":"Brain region-specific expression levels of synuclein genes in an acid sphingomyelinase knockout mouse model: correlation with depression-\/anxiety-like behavior and locomotor activity in the absence of genotypic variation","volume":"25","author":"Brazdis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110812_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.psyneuen.2015.01.007","article-title":"DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY","volume":"53","author":"Canneva","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110812_bib5","article-title":"More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus","volume":"32","author":"Chaturvedi","year":"2019","journal-title":"Gen Psychiatr"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110812_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae062","article-title":"Exploring the anxiolytic potential of NPY by a dipeptidyl peptidase-IV inhibitor in an animal model of PTSD","volume":"27","author":"Dahan","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110812_bib7","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00463.2010","article-title":"Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice","volume":"300","author":"Dobrian","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110812_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbr.2006.04.003","article-title":"Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity","volume":"171","author":"El Yacoubi","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110812_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/17425255.2014.907274","article-title":"The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]","volume":"10","author":"Filippatos","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110812_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.brainresbull.2013.12.007","article-title":"Can fear extinction be enhanced? A review of pharmacological and behavioral findings","volume":"105","author":"Fitzgerald","year":"2014","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110812_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1515\/CCLM.2009.064","article-title":"Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions","volume":"47","author":"Frerker","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110812_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12432","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline","volume":"17","author":"Gault","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110812_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110812_bib14","article-title":"An integrative assay for measuring social aversion and motivation in freely behaving mice","volume":"5","author":"Grammer","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.neuropharm.2025.110812_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1493619","article-title":"Beyond fur color: differences in socio-emotional behavior and the oxytocin system between male BL6 and CD1 mice in adolescence and adulthood","volume":"18","author":"Gryksa","year":"2024","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110812_bib16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nm.3214","article-title":"Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs","volume":"19","author":"Gulbins","year":"2013","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110812_bib17","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.3390\/ijms23158228","article-title":"Social fear affects limbic system neuronal activity and gene expression","volume":"23","author":"Hamann","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110812_bib18","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1038\/s41598-021-87539-7","article-title":"Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice","volume":"11","author":"Hansen","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110812_bib19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/HYPERTENSIONAHA.118.11498","article-title":"DPP (dipeptidyl peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition","volume":"72","author":"Hubers","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2025.110812_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6212983","article-title":"Social isolation stress induces anxious-depressive-like behavior and alterations of neuroplasticity-related genes in adult Male mice","volume":"2016","author":"Ieraci","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.neuropharm.2025.110812_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fneur.2019.00731","article-title":"Enhanced alcohol preference and anxiolytic alcohol effects in Niemann-Pick disease model in mice","volume":"10","author":"Kalinichenko","year":"2019","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110812_bib22","first-page":"1424","article-title":"Effects of DPP-4 inhibitors on brain natriuretic peptide, neuropeptide Y, glucagon like peptide-1, substance P levels and global longitudinal strain measurements in type 2 diabetes mellitus patients","volume":"5","author":"Kalkan","year":"2022","journal-title":"J Health Sci Med"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110812_bib23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00213-019-05199-y","article-title":"Effects of conditioned social fear on ethanol drinking and vice-versa in male mice","volume":"236","author":"Kornhuber","year":"2019","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110812_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110812_bib25","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.3390\/ijms22073695","article-title":"Brain region-dependent effects of neuropeptide Y on conditioned social fear and anxiety-like behavior in male mice","volume":"22","author":"Kornhuber","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110812_bib26","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.3390\/ijms21218220","article-title":"Neuropeptide Y as alternative pharmacotherapy for antidepressant-resistant social fear","volume":"21","author":"Kornhuber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110812_bib27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/0269881119862529","article-title":"Neuropeptide Y reduces expression of social fear via simultaneous activation of Y1 and Y2 receptors","volume":"33","author":"Kornhuber","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110812_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810142","article-title":"Neuropeptide Y reduces social fear in male mice: involvement of Y1 and Y2 receptors in the dorsolateral septum and central amygdala","volume":"22","author":"Kornhuber","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110812_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109847","article-title":"Valence-dependent effects of neuropeptide Y on the expression of conditioned fear and anxiety-like behavior: involvement of the bed nucleus of the stria terminalis","volume":"246","author":"Kornhuber","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110812_bib30","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212573","article-title":"Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges","volume":"8","author":"Koyuncu","year":"2019","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110812_bib31","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1007\/s11357-024-01120-4","article-title":"Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders","volume":"46","author":"Li","year":"2024","journal-title":"GeroScience"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110812_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/01616412.2018.1474840","article-title":"Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss","volume":"40","author":"Li","year":"2018","journal-title":"Neurol. Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110812_bib33","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/molecules27082478","article-title":"Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal","volume":"27","author":"Listos","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2025.110812_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopha.2016.10.098","article-title":"Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress","volume":"85","author":"Magdy","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110812_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104873","article-title":"Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia","volume":"9","author":"Mondragon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110812_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174602","article-title":"Saxagliptin ameliorated the depressive-like behavior induced by chronic unpredictable mild stress in rats: impact on incretins and AKT\/PI3K pathway","volume":"912","author":"Nazeem","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110812_bib37","first-page":"53","article-title":"Sitagliptin attenuates cognitive impairment in the rat model of aluminum-induced Alzheimer's disease","volume":"9","author":"Osman","year":"2019","journal-title":"J. Adv. Pharm. Educ. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110812_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020719","article-title":"Prolonged depression-like behavior caused by immune challenge: influence of mouse strain and social environment","volume":"6","author":"Painsipp","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110812_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115755","article-title":"SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model","volume":"168","author":"Sim","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110812_bib40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00210-020-01838-w","article-title":"Impact of some oral hypoglycemic agents on type 2 diabetes-associated depression and reserpine-induced depression in rats: the role of brain oxidative stress and inflammation","volume":"393","author":"Soliman","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110812_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.npep.2015.09.007","article-title":"The role of neuropeptide Y in fear conditioning and extinction","volume":"55","author":"Tasan","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2025.110812_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0942s63","article-title":"Social fear conditioning as an animal model of social anxiety disorder","author":"Toth","year":"2013","journal-title":"Curr Protoc Neurosci"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110812_bib43","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/npp.2011.329","article-title":"Social fear conditioning: a novel and specific animal model to study social anxiety disorder","volume":"37","author":"Toth","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110812_bib44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13378","article-title":"Proteolytic degradation of neuropeptide Y (NPY) from head to toe: identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and periphery","volume":"135","author":"Wagner","year":"2015","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110812_bib45","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1210\/js.2019-00185","article-title":"Dipeptidyl peptidase 4 inhibition increases postprandial norepinephrine via substance P (NK1 receptor) during RAAS inhibition","volume":"3","author":"Wilson","year":"2019","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110812_bib46","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1007\/s11357-024-01116-0","article-title":"DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease","volume":"46","author":"Yu","year":"2024","journal-title":"GeroScience"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110812_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12847","article-title":"Ceramides affect alcohol consumption and depressive-like and anxiety-like behavior in a brain region- and ceramide species-specific way in male mice","volume":"25","author":"Zoicas","year":"2020","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2025.110812_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110656","article-title":"Early treatment with vildagliptin and linagliptin reduces social fear and prevents the onset of comorbid depression in a mouse model of social anxiety disorder","volume":"279","author":"Zoicas","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110812_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuropharm.2016.03.054","article-title":"Neuropeptide S reduces fear and avoidance of con-specifics induced by social fear conditioning and social defeat, respectively","volume":"108","author":"Zoicas","year":"2016","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110812_bib50","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cells12101355","article-title":"Development of comorbid depression after social fear conditioning in mice and its effects on brain sphingolipid metabolism","volume":"12","author":"Zoicas","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110812_bib51","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41386-025-02146-8","article-title":"Sitagliptin as a therapeutic approach for social anxiety disorder: the role of DPP4 and NPY in modulating social fear and comorbid depressive-like behavior in mice","volume":"50","author":"Zoicas","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110812_bib52","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1038\/npp.2014.156","article-title":"Brain oxytocin in social fear conditioning and its extinction: involvement of the lateral septum","volume":"39","author":"Zoicas","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110812_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177556","article-title":"Dipeptidyl peptidase-4 inhibitors enhance memory retention via neuropeptide Y","volume":"996","author":"Zoicas","year":"2025","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825005209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825005209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:08:32Z","timestamp":1768572512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825005209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0028390825005209"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110812","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting treatment-resistant social anxiety with sitagliptin: Effects on social fear and comorbid depressive-like behavior in a preclinical model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110812"}}